The Chinese Consume...
Health Care: Drugs
Nymox Pharmaceutical Corp. (NYMX: NASDAQ)
$8.60 -0.11 | -1.26%
02/09/12 - 04:00 PM ET
25.03K / 56.40K
Vol / Avg. Vol:8.71 / 8.71
Open / Prev. Close:8.60 - 8.71
Today's Range:6.00 - 9.89
52 Wk Range:6.45%
Performance YTD:TheStreet Rating:
Portfolios with NYMX
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- Userbiotech
- ContributorUnder $5 Stocks at Risk of ...
- UserNeal Wallen
- Usercurrent considerations
- UserSUPRATRADE "BUY IT IMM...
- Usershortyduep Portfolio 1
- UserGRF&PN
- Usertexsts Portfolio 1
- UserBookIT837643
Latest NYMX Headlines from TheStreet
- Biotech Stock Mailbag: Sangamo Biosciences 07.22.11 | 05:07 am
- Nymox Announces Positive New Results In 7 Year Study Of NX-1207 For Benign Prostatic Hyperplasia 03.16.11 | 10:03 am
- Nymox Reports 2010 Financial Results 03.15.11 | 10:03 am
- Biotech Mailbag: BIO CEO Wrap 02.18.11 | 07:02 am
- Nymox: Another Look at Enlarged-Prostate Drug 02.10.11 | 09:02 am
- January 28 Safety Monitoring Committee Meeting For Nymox Pivotal Phase 3 NX-1207 Trials Indicates Favorable Safety Profile 01.31.11 | 11:01 am
- Singular Research Issues "Buy" Rating On Nymox With New Price Target Of $14.50 12.22.10 | 10:12 am
- Recordati And Nymox Pharmaceutical Corporation Announce European Licensing Agreement For NX-1207 12.16.10 | 05:12 pm
- Nymox To Hold Conference Call At 8:30 A.m. Friday, December 17 To Discuss European Licensing Agreement For NX-1207 12.16.10 | 05:12 pm
- Nymox Announces New $15 Million Equity Financing Commitment 11.29.10 | 10:11 am
Press Releases for NYMX
Partner Headlines for NYMX
